Integrated Quantitative Investments LLC Takes $271,000 Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Integrated Quantitative Investments LLC acquired a new position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 4,900 shares of the specialty pharmaceutical company's stock, valued at approximately $271,000.

A number of other hedge funds have also bought and sold shares of the business. Geode Capital Management LLC lifted its position in shares of ANI Pharmaceuticals by 0.9% during the fourth quarter. Geode Capital Management LLC now owns 428,999 shares of the specialty pharmaceutical company's stock worth $23,720,000 after acquiring an additional 3,774 shares in the last quarter. Loomis Sayles & Co. L P lifted its holdings in ANI Pharmaceuticals by 11.2% during the 4th quarter. Loomis Sayles & Co. L P now owns 194,185 shares of the specialty pharmaceutical company's stock worth $10,735,000 after purchasing an additional 19,568 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new stake in ANI Pharmaceuticals during the 4th quarter worth about $166,000. Sei Investments Co. boosted its stake in ANI Pharmaceuticals by 13.7% in the 4th quarter. Sei Investments Co. now owns 22,774 shares of the specialty pharmaceutical company's stock worth $1,259,000 after purchasing an additional 2,752 shares during the period. Finally, Teacher Retirement System of Texas grew its holdings in ANI Pharmaceuticals by 18.9% during the 4th quarter. Teacher Retirement System of Texas now owns 4,999 shares of the specialty pharmaceutical company's stock valued at $276,000 after buying an additional 793 shares in the last quarter. 76.05% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

ANI Pharmaceuticals Price Performance

Shares of ANIP traded up $3.00 during midday trading on Friday, reaching $68.12. The stock had a trading volume of 291,286 shares, compared to its average volume of 267,570. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. The company has a market capitalization of $1.48 billion, a price-to-earnings ratio of -123.85 and a beta of 0.49. The company's 50-day moving average is $62.34 and its 200 day moving average is $59.07. ANI Pharmaceuticals, Inc. has a 12-month low of $52.50 and a 12-month high of $70.00.

Insiders Place Their Bets

In other ANI Pharmaceuticals news, SVP Krista Davis sold 1,000 shares of the company's stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $60.20, for a total transaction of $60,200.00. Following the completion of the sale, the senior vice president now directly owns 68,624 shares in the company, valued at $4,131,164.80. This represents a 1.44 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, VP Meredith Cook sold 400 shares of ANI Pharmaceuticals stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $63.33, for a total value of $25,332.00. Following the completion of the transaction, the vice president now owns 80,545 shares in the company, valued at approximately $5,100,914.85. This represents a 0.49 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 3,200 shares of company stock valued at $191,776 over the last quarter. 12.70% of the stock is owned by corporate insiders.

Analyst Ratings Changes

ANIP has been the topic of a number of recent analyst reports. Jefferies Financial Group assumed coverage on shares of ANI Pharmaceuticals in a report on Friday, March 14th. They issued a "buy" rating and a $80.00 price target on the stock. JPMorgan Chase & Co. initiated coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, March 12th. They issued an "overweight" rating and a $85.00 target price on the stock. StockNews.com lowered shares of ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Tuesday. HC Wainwright reiterated a "buy" rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a research report on Monday, March 17th. Finally, Guggenheim reissued a "buy" rating and set a $86.00 price objective on shares of ANI Pharmaceuticals in a research note on Friday. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, ANI Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus price target of $79.75.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.